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1. Introduction 
1.1 Therapy of Head and Neck Squamous Cell Carcinoma 
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer. The 
worldwide incidence increases with age, especially after 50 years old, exceeding half a 
million cases annually. It carries a mortality rate of over 50%, with stagnant 5-year survival 
rates (Siegel et al., 2011; Méry et al., 2016). HNSCC often develop with preneoplastic fields 
of genetically altered cells on the surface of the oral cavity, oropharynx, nasal cavity, sinuses 
or larynx. It is thought to be caused by the molecular effects of environmental carcinogens. 
Although many epidemiological studies have conclusively identified carcinogen exposures of 
tobacco and alcohol that are associated with an increased risk of HNSCC, human 
papillomavirus (HPV) infection, especially HPV-16 and HPV-18, has been increasingly 
associated with this group of cancers (Leemans et al., 2010; Michaud et al., 2014). HPV 
associated HNSCC comprise a distinct molecular, clinical and pathologic entity that has a 
markedly better prognosis than HPV negative cancers. Whether the intense therapy is too 
aggressive in HPV positive patients remains a controversial issue (Ramshankar et al., 2013). 
Future therapeutic concepts for HNSCC may be personalized in relation to HPV-status to 
avoid unnecessary toxicity, which makes understanding of the relationship between HPV and 
HNSCC more important than ever.  
HNSCC therapies include surgical intervention, chemotherapy (e.g. cisplatin, axitinib) and 
radiation. Surgery and radiotherapy remain the primary modalities for management of early 
and loco regionally advanced HNSCC. The existing chemotherapy is non-selective and 
associated with significant adverse effects. These aggressive therapies for HNSCC have done 
little to improve overall 5 years survival. For patients with recurrent and metastatic disease, 
the therapeutic options are further limited (Méry et al., 2016; Leemans et al., 2010; Bonner et 
al., 2006). The gene therapy, immunotherapy and molecularly targeted therapy (e.g. 
cetuximab, EGFR inhibitor) provide a promising approach and are having been a major focus 
of research over the decades. Therefore, integration of molecular imaging and dose adaptation 
during treatment is the future directions which are promising strategies to improve the 
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efficacy and minimizing associated toxicity accuracy (Leemans et al., 2010; Sacco and 
Worden, 2016). 
1.2 Nanoparticles Technologies for Cancer Medicine 
Nanotechnology commonly refers to materials and devices up to several hundred nanometers 
or less. The application of nanotechnology to medicine, designated as nanomedicine has 
greatly accelerated advances in detection, diagnosis, imaging and therapy of many diseases. 
Use of nanoparticles as drug delivery systems in cancer therapy is a growing research field 
over the past two decades (Alexis et al., 2010; Wang et al., 2012; Matsumura and Maeda, 
1986). 
Classical potent chemotherapeutic agents have the disadvantage of affecting both tumor cells 
and normal cells, with the concomitant secondary effects including cytotoxicity. Some of 
these chemotherapeutic associated problems have been solved by the use of nanoparticles as 
drug delivery systems. By encapsulating a variety of chemotherapeutic agents inside 
nanoparticles, the bioavailability of the drugs can be improved including stability, solubility, 
biodistribution and blood circulation half-life (Wang et al., 2012; Ochekpe et al., 2009). One 
important advantage of these nanoparticles is that they accumulate in specific tissue, as well 
as solid tumors. This effect is called enhanced permeability retention effect (EPR) and is 
based on the higher leakage of capillaries in solid tumors compared to healthy tissue (Fig. 1.1). 
Selective accumulation in tumor sites due to EPR effect increases local therapeutic drugs 
concentration, consequently, the required dose of drug is lower and the reduced drug 
concentration in healthy tissue minimizes undesirable toxic effects (Matsumura and 
Maeda,1986; Ochekpe et al., 2009; Minko et al., 2000; Maeda, 2001). 
A large number of nanoparticles as drug delivery system have been developed for cancer 
therapy, including organic and inorganic materials (Bangham et al., 1965; Torchilin, 2005; 
Danhier et al., 2009; Ochekpe et al., 2009). The surface of nanoparticles is further modified 
with small functional groups that increase their specificity targeting potential (Fig. 1.2). 
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Fig. 1.1 Schematic representation of the enhanced permeability and retention effect (EPR 
effect): Nanoparticle size plays a significant role in their ability to extravasate from the 
bloodstream and reach the tumor tissues which are leaky and disorganized. This however does 
not occur in normal tissue as the blood vessels are well formed and non-porous. Small 
molecules are capable of entering both tumor and normal tissue (Draw by Hanwen Chu). 
 
 
Fig. 1.2 Nanoparticle as drug delivery system is characterized by their physicochemical 
structures. (Picture excerpted from article: Nanoparticle Technologies for Cancer Therapy; 
Alexis et al., 2010). 
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Magnetic nanoparticles (MNPs) as drug targeting carriers have attracted significant attention 
because of the promising site-directed application in the field of nanomedicine which is 
directed at the target tissue by means of an external magnetic field. Materials most commonly 
used for magnetic drug delivery contain metal or metal oxide nanoparticles which are 
well-tolerated. Conjugation of magnetic materials with drugs, in combination with an external 
magnetic field to target the nanoparticles has additionally emerged as a promising strategy of 
drug delivery. MNPs based drug delivery is a sophisticated overall concept and a multitude of 
magnetic delivery carriers have been developed. Targeting mechanism-exploiting, 
tumor-specific attributes are becoming more and more sophisticated. The same is true for 
controlled-release strategies for the diseased site (Gómez-Sotomayor et al., 2015; Tietze et al., 
2015). 
Lipid vesicles are the first and most used nanoparticle drug delivery system which were later 
known as liposomes or nanoliposomes. It is formed by expontaneous self-assembly of 
amphiphilic phospholipids such as phosphatidylcholine, phosphatidylglycerol or 
phosphatidylserine, which can also be found in the human body (Abreu et al., 2011; 
Khosravi-Darani et al., 2010; Ochekpe et al., 2009). Hydrophilic drugs can be encapsulated 
into the central aqueous phase, while hydrophobic molecules can be embedded into the 
hydrophobic parts of the lipid bilayer (Fig. 1.3). Physicochemical properties of liposome can 
be precisely changed to control surface charge, size and functionality (Abreu et al., 2011). 
Currently, there are around ten liposomal-drug formulations for different conditions in clinical 
use and hundreds of ongoing clinical trials are registered by US Food and Drug 
Administration (FDA) (Ochekpe et al., 2009; Wang et al., 2012; Matsuzaki et al., 2012), The 
most common ones are DaunoXome (liposomal daunorubicin) for blood tumors, Doxil and 
Lipod-dox (PEGylated liposomal doxorubicin) for ovarian and breast cancers, and for 
Kaposi’s sarcoma patients (Wang et al., 2012). There are currently few liposomal formulations 
with triggered drug release approved for clinical use or in early phases of clinical trials. 
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Fig. 1.3 General Structure of a liposome (Picture excerpted from article: Recent Progress in 
Liposome Production, Relevance to Drug Delivery and Nanomedicine; Koynova and Tenchov, 
2015). 
 
1.3 Sphingomyelinase in biologicals systems 
Like phosphatidylcholine, sphingomyelin (SM) are considered as an important structural 
component and tends to be of the greatest concentration of the plasma membrane, especially 
in the outer leaflet of cells (Testi, 1996). SM and the enzyme sphingomyelinase (SMase), 
which converts SM to ceramide, are increasingly recognized as bioactive markers involved in 
numerous biological functions. Increase of SMase and/or ceramide have been confirmed to be 
associated with various cellular physiologic and pathophysiologic processes that include cell 
cycle, apoptosis and inflammatory responses. The most studied form of sphingomyelinases is 
acid form. Different stimuli including ionizing radiation, heat or chemotherapeutic drugs 
trigger a translocation of the acid sphingomyelinase (ASMase) localized in intracellular 
vesicles (Lysosome ASMase) to fuse with the cell membrane and expose the ASMase on the 
outer leaflet of the cell membrane (Secretory ASMase) (Grassme et al., 2001) (Fig. 1.4).  
The release of ceramide from sphingomyelin by secretory ASMase in the cell membrane 
results in the formation of ceramide-enriched microdomains which serve the transmission of 
the stress signal into the cell. This sphingolipid ASMase / ceramide signaling pathway 
occupies a prominent position in principal physical and molecular early events induced at the 
plasma membrane after radiation (Corre et al., 2010; Vit and Rosselli, 2003). 
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A  B  
Fig. 1.4 (A) Different stimuli trigger a translocation of the ASMase onto the extracellular 
leaflet of the cell membrane. The formation of ceramide from sphingomyelin by ASMase in 
the cell membrane results in the formation of ceramide-enriched microdomains which serve 
the transmission of the stress signal into the cell (Picture excerpted from article: Ceramide in 
malignant tumors; Gunawardena et al., 2004). (B) ASMase transport to the extracellular part 
of PM from lysosome (Picture adapted from article: Membrane raft-lysosome redox 
signalling platforms in coronary endothelial dysfunction induced by adipokine visfatin; Xia et 
al., 2011). 
The reaction product of SM, ceramide, has been regarded being part in apoptosis signaling by 
forming ceramide-enriched microdomains in cell membranes. It was shown in biophysical 
model membrane studies the ceramide domain formation in both fluid and gel state 
phosphatidylcholine membranes when ceramide has been added (Holopainen, et al., 1997; 
Huang et al., 1996). Ceramide-enriched microdomains have been shown to exclude 
cholesterol from cell membranes, alter membrane fluidity, change membrane curvature and 
induce transbilayer flip-flop (Megha and London, 2004; Rebillard, et al., 2007; Ira and 
Johnston, 2008; López-Montero, et al., 2005). The membrane invagination and vesiculation of 
the bilayer result from augmented bending rigidity of the ceramide-containing domains have 
been observed (Fig. 1.5) (Holopainen, et al., 2000; Nurminen, et al., 2002).  
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A B  
C   D  
○phosphatidylcholine, ■Sphingomyelin, ●ceramide  phosphoryl choline 
Fig. 1.5 (A) The lipids in the phosphatidylcholine /Sphingomyelin monolayer are randomly 
distributed; (B) Hydrolytic cleavage of the phosphocholine head group from SM by 
sphingomyelinase generates ceramide; (C) Leaflet containing ceramide condenses and the 
formed ceramide segregates into a domain (D) Tendency of ceramide to form inverted 
on-lamellar phases, an invagination is formed by the ceramide-enriched domain. (Picture 
excerpted from article: Vectorial budding of vesicles by asymmetrical enzymatic formation of 
ceramide in giant liposomes；Holopainen, et al., 2000). 
 
1.4 Indocyanine Green (ICG) Fluorescent Imaging for Clinical Use 
Fluorescence Imaging (FI) is one of the most popular imaging methods in biomedical 
sciences for visualization of cells and tissues. ICG is considered as an ideal contrast agent 
(820 nm wavelength NIR, near infrared) with minimal interference from tissue and blood 
auto-fluorescence (500-600 nm). It is a clinically approved NIR fluorescence dye and has 
been used in some medical applications routinely already for decades including retinal 
angiography, liver clearance tests and cardiac output monitoring (Nguyen and Tsien, et al., 
2013). ICG has several excellent clinical properties: (i) patient safety: nontoxic and 
nonionizing, (ii) ideal for angiography: confinement to the vascular compartment through 
efficiently binding to blood lipoproteins, that is, it does not leak from circulation, (iii) short 
life time in blood circulation allowing repeated applications, (iv) good signal to noise ratio 
(SNR): there is not much NIR auto-fluorescence in tissue giving low noise background, (v) 
deep imaging: operates in tissue optical window (NIR) and (vi) simple and cheap imaging 
8 
 
 
devices. There have been very recently used ICG in sentinel lymph node navigation (SLN) 
detection in lung and prostate cancer patients (Jarmo et al., 2012; Zhang et al., 2008; 
Frangioni, 2008). 
However, ICG is limited by its aqueous instability, concentration-dependent aggregation and 
rapid degradation for medical diagnosis (Jarmo et al., 2012; Kraft and Ho, 2014; Desmettre et 
al., 2000). To overcome these limitations, ICG encapsulated to liposomes was developed that 
can enhance ICG stability for light exposure and storage. It can also maximize ICG 
fluorescence intensity and stability (Fig. 1.6). Finally, liposome can be engineered to be 
multi-functional with the ability to target diseased tissue, carry imaging agents for detection 
and deliver multiple therapeutic agents for combined delivery. 
 
Fig. 1.6 ICG is incorporated into the hydrophobic domains of the lipid bilayer. (Picture 
excerpted from article: Interactions of Indocyanine Green and Lipid in Enhancing 
Near-Infrared Fluorescence Properties: The Basis for Near-Infrared Imaging in Vivo；Kraft 
and Ho, 2014). 
 
1.5 The hypothesis of this study 
Multimodal capabilities of nanoparticle delivery system offer the opportunity to develop 
novel approaches to deliver drugs that may result in alternative or complementary therapeutic 
options for the treatment of disease. Our research group has designed a magneto-enzymatic 
sensitive liposome (MESL), which contains ICG for fluorescent labeling and cisplatin as a 
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chemotherapeutic agent for targeted optical imaging and local drug release. The MESL 
contains sphingomyelin distinguish from previous liposomes other scientists researched. SM 
can be hydrolyzed by acid ASMase, which is excreted in site of cancer and thus subsequently 
causes a local enzymatic drug release from SM-liposomes. Iron particles added into the lipid 
bilayer of the liposome will amplify the activation process through Brownian motion on lipids, 
when alternating magnetic field (AMF) is used. When these two activation mechanisms are 
combined locally controlled drug release is possible. (Fig. 1.7). 
 
 
Fig. 1.7 Schematic representation of Magneto-Enzymatic Sensitive Liposome (MESL). 
 
This environment sensing ICG-MESL probe has becomes optical/fluorescence changes after 
reacting with SMase and additional AMF, which can be detected and thus follow the fate of 
the liposomes in vivo. First objective was to study and find the optimal concentration of ICG 
in MESL for imaging purposes. We also wanted to quantify endogenous ASMase available in 
the squamous tumor cells. While our disease model as squamous cell carcinoma SCC9 and 
UDSCC2 cells were chosen to evaluate the ASMase activity. First, we studied ASMase 
activity in a situation where stress was induced through irradiation or cisplatin. HNSCC mice 
model is already established previously in our clinic for vivo studies. We wanted to study 
ASMase activity also in this mice model in which SCC9 cells were injected to grown in mice 
and further analyze the SMase activity in those tumors. Therefore, the aim of this study was to 
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evaluate the optical properties of environment sensing ICG-MESL probe; Vitro 
characterization of ASMase activity as a cell stress indicator in HNSCC; Vivo 
characterization of ASMase activity of mice tumor and muscle.  
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2. Methods 
2.1 Optical properties of environment sensing ICG-MESL probe 
2.1.1 Fluorescence of ICG-MESL and pure ICG in blood 
Fluorescent dye of ICG (Sigma, Germany) was diluted into 0.033 mg/ml, 0.066 mg/ml, 0.165 
mg/ml, and 0.330 mg/ml with PBS (Biochrom, Germany). 10 µl of different concentration of 
ICG was added into 4-strip PCR tubes (Thomas Scientific, Germany) together with 90 µl 
blood and mixed carefully. Four-strip PCR tubes were placed on a phantom and measured in 
the fluorescence molecular tomography (FMT2500) image system (Perkin Elmer, USA) 
which is commonly applied for quantitative three-dimensional (3D) vivo imaging (Fig. 2.1). 
Images were created and analyzed with TrueQuant (GenxPro, USA). Each experiment was 
performed in triplicate. 
 
A  B  
Fig. 2.1 Fluorescence of ICG was measured by fluorescence molecular tomography (FMT). 
 
Setting the parameters of FMT program as below: Laser Channel: 790 nm; Agent: 800 
conjugates; Cassette Depth: 19 mm. Reflectance image areas were captured and modified 
manually as we needed (72 points). Regions of interest (ROIs) were drawn with the same size 
of ellipsoid around the tubes and the mean value of the fluorescent signal outputs 
automatically (Fig. 2.2). 
 
Phantom 
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A  B  
 
C  D  
Fig. 2.2 (A) Capture the reflectance image area (Red rectangle). (B) Measuring the 
fluorescence point by point (△ phantom ● measuring point). (C) Regions of interest (ROIs) 
was drawn with the same size of ellipsoid around the tubes (Yellow ellipsoid). (D) 
Fluorescent signal of pure ICG. 
 
MESL was from Prof. Oula Penate Medina’s research group, Molecular Imaging North 
Competence Center (MOIN CC), University Hospital Schleswig-Holstein Campus Kiel 
(UKSH). MESL containing varying concentration of ICG (0.05 mg/ml, 0.10 mg/ml, 0.25 
mg/ml, and 0.50 mg/ml) was diluted into the final ICG concentration of 0.033 mg/ml, 0.066 
mg/ml, 0.165 mg/ml and 0.330 mg/ml in PBS. Fluorescence was measured as described 
previously. Each experiment was performed in triplicate. 
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2.1.2 Fluorescence change of ICG-MESL with SMase 
MESL containing varying concentration of ICG (0.05 mg/ml, 0.10 mg/ml, 0.25 mg/ml, and 
0.50 mg/ml) were diluted into the final concentration of 0.033 mg/ml, 0.066 mg/ml, 0.165 
mg/ml and 0.330 mg/ml in PBS. 10 µl of different concentration of ICG-MESL was added 
into 4-strip PCR tubes together with 90 µl blood and 10 µl of 1.0 U/ml SMase (from B. 
cereus；Sigma, Germany). Samples were mixed carefully and incubated in the room 
temperature for 10 minutes. 10µl PBS instead of SMase was added into the control group. 
Measurement and analysis were done as previously described. Each experiment was 
performed in triplicate. 
2.1.3 Fluorescence change of ICG-MESL with SMase and AMF     
ICG loaded MESL was prepared containing 0.330 mg/ml ICG in PBS. 10 µl of this 
ICG-MESL was added into 4-strip PCR tubes together with 90 µl blood. The samples were 
measured for the first time. Then 10 µl different concentration of SMase was added, resulting 
final activities of 0.364 U/ml, 0.727 U/ml, 1.091 U/ml and 1.454 U/ml. The samples were 
measured after 20 minutes incubation in the room temperature. The AMF group of 4-strip 
PCR tubes was treated with AMF for additional 20 minutes incubations in room temperature 
before measurement (Fig. 2.3). The fluorescence percentage increases of each sample were 
compared. Each experiment was performed in triplicate. 
     
Fig. 2.3 AMF device where the coil size allows samples to be treated. 
 
Samples copper coil 
Heatsink 
Ventilator 
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2.2 In vitro characterization: ASMase activity as a cell stress indicator in HNSCC lines 
2.2.1 Preparation of carcinoma cells 
2.2.1.1 Culture of carcinoma cells 
SCC9 cell lines were kindly provided by Prof. Yahya Açil, Scientific laboratories, department 
of Oral and Maxillofacial, Plastic Surgery, UKSH. Cells were maintained in a complete 
medium containing DMEM (Biochrom, Germany) supplemented with 10% FCS (HyClone, 
UK), 100 IU/ml of penicillin (Biochrom, Germany), 100 µg/ml of streptomycin (Biochrom, 
Germany) and 400 ng / ml hydrocortisone (Biochrom, Germany). Cells were cultivated in 5% 
CO2 humidified atmosphere at 37 °C. Medium was changed every three days. 
UDSCC2 cell lines were kindly provided by Dr. Tibor Görögh, Clinic of Ear, Nose, Throat, 
Head and Neck Surgery, UKSH. Cells were maintained in a complete medium containing 
DMEM supplemented with 10% FCS, 100 IU/ml of penicillin, and 100 µg/ml of streptomycin. 
Cells were cultivated in 5% CO2 humidified atmosphere at 37 °C. Culture medium was 
refreshed every three days. 
2.2.1.2 Passage of carcinoma cells 
Until the cells reached 60–80% confluences, cells were harvested by tryptic digestion. 
Medium was aspirated, cells were washed with warmed PBS and detached by 5 minutes 
incubation in 0.01% trypsin-EDTA (Biochrom, Germany) at 37 °C. The suspension was 
transferred to a sterile 50 ml falcon tube with cell culture medium to neutralize the trypsin 
reaction and centrifuged at 1200 rpm for 5 minutes. After aspirating the supernatant, the cells 
were resuspended in a small volume of cell culture medium and counted with hemocytometer. 
Finally, 1×105 cells were subculture in 75 cm2 cell culture flasks. 
2.2.1.3 Cell frozen of carcinoma cells 
After centrifugation prior to harvesting and counting of cells, the pellet of cells was 
resuspended in warm cryopreservation medium containing 90% FCS, 10% DMSO (Sigma, 
USA) in a final concentration of 1×106 per vial. The vials were maintained in an alcohol 
freezing container and transferred to a -80 °C refrigerator in which the vials were cooled 
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slowly, at approximately 1 °C every minute, until they reach -80 °C. The cells were stored at 
-80 °C overnight prior to transfer to a liquid nitrogen container for long term storage. 
2.2.2 Preparation of Keratinocyte 
2.2.2.1 Culture of Keratinocyte 
Keratinocyte cell lines were kindly provided by Prof. Dr. Yahya Açil, Head of the scientific 
laboratories, department of Oral and Maxillofacial, Plastic Surgery, UKSH. Keratinocyte were 
maintained in Defined Keratinocyte- serum free medium (Defined K-SFM；Gibco, USA) 
supplemented with 0.005 µg/ml EGF human recombinant (Gibco, USA) and 0.05 mg/ml 
bovine pituitary extract (Gibco, USA), 100 IU/ml of penicillin, 100 µg/ml of streptomycin. 
Cells were cultivated in 5% CO2 humidified atmosphere at 37 °C. Medium change took place 
every two days until the cells reached 60–80% confluences.  
2.2.2.2 Passage of Keratinocyte 
The medium was aspirated and the cells were harvested by washing with warmed PBS when 
the cells reached 60–80% confluence. All the cells were detached by brief incubation in 1.5 
ml accutase (PAA, Austria) at 37 °C. The suspension was transferred a sterile 50 ml falcon 
tube with Defined K-SFM medium to neutralize the enzyme reaction and centrifuged at 1200 
rpm for 5 minutes. After aspirating the supernatant, the cells were resuspended in a small 
volume of cell culture medium and counted using a hemocytometer. Finally, 1×105 cells 
subculture in 75 cm2 cell culture flask. Keratinocyte at passage 2-3 were used in the 
experiment (Fig. 2.4). 
A B C  
Fig. 2.4 SCC9 (A), UDSCC2 (B), Keratinocyte (C) under the electron microscope (phase 
contrast microscope × 20). 
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2.2.3 ASMase activity as a cell stress indicator after irradiation 
2.2.3.1 Cells preparation for irradiation 
Half million of SCC9 or UDSCC2 cells were subculture in 75 cm2 cell culture flask day 
before. The complete medium was aspirated carefully and changed the medium to 3 ml of 
PBS to each flask just before irradiation.  
Three different doses of irradiation (12 Gy, 24 Gy and 36 Gy) were given to the cells. Control 
group was treated otherwise similarly but without irradiation. Supernatant was preserved 
immediately after irradiation for the measurement of ASMase activity. Each experiment of 
SCC9 and UDSCC2 was performed in triplicate. 
Three flasks of Keratinocytes were treated with irradiation (24 Gy) and another three kept as 
controls. Supernatant from the cell flasks was collected immediately after irradiation for the 
measurement of ASMase activity. Experiment was performed three times. 
2.2.3.2 ASMase activity measurement after irradiation 
ASMase activity was measured using an Amplex Red Sphingomyelinase Assay Kit (Thermo 
Fisher, Germany). The kit utilizes a multi-enzyme reaction that generates a fluorescent 
product, equal to produced ceramide, to quantify ASMase activity. A two-step assay of SMase 
activity was performed according to the manufacturer’s instructions. The SMase reaction was 
carried out in an acidic buffer. 50 µl of acidic reaction buffer (50 mM sodium citrate, pH 5.0), 
10 µl of 5 mM sphingomyelin in 2% Triton-X were added to each well of a 96-well plate prior 
to the addition of 50 µl supernatant of cells treated with irradiation. The reactions were 
incubated at 37 °C for 60 minutes. Phosphocholine (end product of lysis) detection reaction 
was carried out in a neutral pH environment. 100 µl of base-buffered Amplex Red detection 
solution (100 µM Amplex Red, 2 U/ml horseradish peroxidase, 0.2 U/ml choline oxidase, 
8U/ml alkaline phosphatase, 100 mM Tris–HCl, pH 8.0) was added to each well. The reaction 
was incubated at 37 °C for 30 min. Fluorescence values were determined by 
SPECTRAFLUOR Plus (Tecan, Germany) using an excitation filter of 550 nm and an 
emission filter of 595 nm. Wells containing hydrogen peroxide solution were incorporated as 
positive reaction controls. Fluorescence values were corrected by subtracting the background 
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fluorescence represented by blank wells containing only acidic reaction buffer, sphingomyelin, 
and base-buffered Amplex Red detection solution. Each experiment was performed in 
triplicate. 
2.2.3.3 Evaluation of cell lines viability after irradiation 
MTT assay (Roche, Germany) was applied to evaluate the viability of the treated cells. MTT 
salt is cleaved by mitochondrial dehydrogenase in the metabolic active cells and is reduced to 
an insoluble formazan crystal which displays a purple color. The color was detected by a 
scanning multi-well spectrophotometer (Molecular Devices, USA). 
Carcinoma cells were seeded at a density of 5×104 cells/well in 96-well plate. Three different 
doses of irradiation (12 Gy, 24 Gy and 36 Gy) were given. Another two plates were prepared, 
one for control and the other one as standard curve without irradiation. Serial dilutions (1:2) 
were made using complete medium as the diluents. Cell densities ranged from approximately 
50, 000 to 780 cells/well in 100 µl medium with 3 replicates per density. Cells were allowed 
to grow overnight at 37 °C in a humidified 5% CO2 environment. 
Keratinocyte were seeded at a density of 5×104 cells/well in 96-well plate and treated with 
irradiation 24 Gy. Another two plates were prepared, one for control and the other one as 
standard curve without irradiation. Serial dilutions (1:2) were made using complete medium 
as the diluents. Cell densities ranged from approximately 50, 000 to 780 cells/well in 100 µl 
medium with 3 replicates per density. Cells were allowed to grow overnight at 37 °C in a 
humidified 5% CO2 environment.  
Supernatant of each well was aspirated 6 hours after irradiation, and 10 µl of MTT (5 mg/ml) 
with 90 µl complete medium were added to wells and the plates which were incubated for 4 h 
at 37 °C. 100 µl of solubilization buffer (10% SDS in 0.01M HCl) was added to the wells and 
the plates were incubated at 37 °C overnight. After the incubation, the absorbance was 
measured at 550 nm in a scanning multi well spectrophotometer (Molecular Devices, USA). 
2.2.3.4 Cisplatin release from Cisplatin-MESL after irradiation 
The SCC9 cells (5×105) were subcultured in 75 cm2 cell culture flask day before the treatment. 
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Nine flasks were prepared for three different doses of irradiation and three flasks were 
prepared without irradiation as control group. Just before irradiation, culture medium was 
replaced with 3 ml PBS as described previously. After irradiation 500 µl of cisplatin loaded 
MESL (Cisplatin-MESL) were added to each flask and incubated for an hour at room 
temperature in shaking. The media from flask was collected and dialyzed against 45 ml PBS 
for 24 hours in Snake Skindialysis bag (Thermo Scientific, Germany) (Fig. 2.9). Released 
cisplatin from outside of the Snake Skin dialysis bag and cisplatin loaded in MESL inside 
were analyzed by measuring the absorbance at 301 nm in spectrometer (Agilent, Germany). 
The percentage release of cisplatin was calculated and background corrected by the control 
group. Experiment was performed in triplicate. 
              
Fig. 2.9 The media was collected and dialyzed against PBS for twenty-four hours in shaking. 
2.2.3.5 ASMase inhibition study in SCC9 after irradiation 
Half million SCC9 cells were subculture in 75 cm2 cell culture flask day before. Media were 
aspirated and cells were cultured with 10 ml fresh medium containing 100 µl/ml desipramine 
(dissolved in 304 µl ethanol), ASMase inhibitor (Elojeimy, et al., 2006). For control cells 304 
µl of plain ethanol was added. The inhibitor was incubated for 2 hours at 37 °C in a 
humidified 5% CO2 environment and then the medium was changed to 3ml PBS before the 
cells were subjected to irradiation (24 Gy). Cells treated without ASMase inhibitor or without 
irradiation were used as control groups. After irradiation, ASMase activity was measured and 
ability to release the cisplatin was studied as previously described (2.3.3.4 and 2.3.4). The 
experiments were performed three times. 
Cisplatin 
loaded MESL 
Free 
Cisplatin  
Medium in  
dialysis  
membrane 
Free cisplatin 
 in PBS 
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2.2.4 ASMase activity as a cell stress indicator after cisplatin treatment 
2.2.4.1 Cells preparation for cisplatin treatment 
Cells (SCC9 or UDSCC2) were prepared day before the experiment. Serial dilutions (1:2) 
were made using complete medium as the diluents. Cell densities ranged from approximately 
15, 000 to 234 cells/well in 100 µl medium with 3 replicates per density as a standard curve. 
The treatment group were seeded at a density of 1.5×104 cells/well in 96-well plate Cells was 
allowed to grow overnight at 37 °C in a humidified 5% CO2 environment.  
2.2.4.2 ASMase activity measurement after cisplatin treatment 
Medium was removed and replaced with 100 µl of different concentration (0 µM as control, 
0.1 µM/ml, 1 µM/ml, 10 µM/ml and 100 µM/ml) of cisplatin (Sigma, Germany) diluted in 
serum-free medium. Cells were treated with the drug for 12 hours, 24 hours and 48 hours and 
the incubation were terminated at the same time in all groups. Fifty µl supernatant were 
transferred to a new 96-well plate and ASMase activity from the supernatant was measured 
using an Amplex Red Sphingomyelinase Assay Kit as described previously. Experiment was 
carried out in triplicate. 
2.2.4.3 Evaluation of cell lines viability after cisplatin treatment 
After ASMase activity measurement, the medium was removed, 10 µl of MTT (5 mg/ml) with 
90 µl complete medium were added to each well and the plate was incubated for 4 h at 37 °C. 
Then 100 µl of solubilization buffer (10% SDS in 0.01 M HCl) was added to the wells and the 
plates were incubated at 37 °C overnight. After the incubation, the absorbance was measured 
at 550 nm in a scanning multi well spectrophotometer (Spectra max plus, Molecular Devices). 
Standard curve derived from automatically.  
2.3 In vivo characterization: aSMase activity of HNSCC and muscle in mouse 
2.3.1 HNSCC mouse model 
2.3.1.1 Cells preparation for HNSCC mouse 
Five million SCC9 cells in 1 ml complete medium were transferred to the Eppendorf tube, 
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and centrifuged at 1200 rpm for 5 minutes. After aspirating the supernatant, the cells were 
resuspended with 100 µl PBS carefully and cooled for 10 minutes on ice. 100 µl Matrigel 
(Corning, Germany) kept at low temperature was combined with precooled cell suspension, 
resulting in a final cell concentration of 2.5 x 107 cells / ml. All equipment and reagents, 
including syringes (Becton, USA), pipettes, and sterile Eppendorf tubes are chilled on the ice 
prior to injection. 20 µl cell suspension with matrigel was filled into the precooled syringes, 
resulting in a final cell number 5 x 105 cells / syringe. 
2.3.1.2 Mouse model construction 
Ten NMRI-Foxn1nu/foxn1nu female Mice were obtained from Roger JANVIER (Roger 
JANVIER, Germany) at the age of 5 weeks and quarantined for one week before use. The 
animal experiments were performed in accordance with the German ethical approval of 
animal experiments and had received approval by institute authorities. Mice were anesthetized 
with 1-2% isoflurane and injected at the middle of the mouth floor for SCC9 xenografts under 
the guidance of small animal ultrasound (Fig. 2.12). All mice were kept in a temperature and 
humidity-controlled environment with a 12-hour light-dark-cycle and access to food and 
water ad libitum. The mice were observed for tumor’s growth every week with small animal 
ultrasound until the 50th day after implantation.  
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Fig. 2.12 Implantation of SCC9 xenografts in the middle of mouth floor under the guidance of 
small animal ultrasound. 
 
2.3.2 ASMase activity of HNSCC and muscle in mouse 
Ten mice were sacrificed, and two samples of each mouth floor carcinoma and hind leg 
muscle were excised from each mouse. The weight of the tissue samples was scaled and 100 
µl of acidic reaction buffer (50 mM sodium citrate, pH 5.0), 10 µl of 5 mM sphingomyelin in 
2% Triton-X were added. The samples were shaken at 350 rmp at 37 °C for 60 min 
(Thermomixer comfort). ASMase activity was measured as follows: 100 µl supernatant was 
transferred to 96-well plates, and 100 µl of base-buffered Amplex Red detection solution (100 
µM Amplex Red, 2 U/ml horseradish peroxidase, 0.2 U/ml choline oxidase, 8U/ml alkaline 
phosphatase, 100 mM Tris–HCl, pH 8.0) was added to each well. The detection reactions 
were incubated at 37 °C for 30 min. Fluorescence values were detected as described 
previously and ASMase activity was standardized by weight of the samples. 
 
 
 
 
 
 
 
 
Needle 
Matrigel with SCC9  
Needle 
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3. Results 
3.1 Optical properties of environment sensing ICG-MESL probe 
3.1.1 Fluorescence of ICG-MESL and pure ICG in blood 
The fluorescence signal between ICG-MESL and pure ICG was compared to identify the 
optical properties of ICG in different environment. The signal of ICG-MESL is significantly 
higher than pure ICG in the concentrated dilution (p< 0.01). The fluorescence signal of 
ICG-MESL climbed dramatically with linear concentration effects. Nevertheless, the 
fluorescence of pure ICG increases until it reaches a plateau at the concentration of 0.0165 
mg/ml (Fig. 3.1). It appears that ICG-MESL has apparent advantage when measuring 
fluorescence intensity. 
 
Fig. 3.1 FMT fluorescence of ICG-MESL and pure ICG in blood. Lines denote the mean 
±standard error of the mean (SD). **, p< 0.01, Independent-Sample T-Test 
 
3.1.2 Fluorescence change of ICG-MESL with SMase 
Effects in fluorescence after enzymatic manipulation of MESL was studied. The significant 
increase of signal was observed in the ICG-MESL at the concentration of 0.030 mg/ml 
(p<0.01) (Fig. 3.2). This concentration we chose to use in the future in vitro and cell studies 
and in the animal experiment. The enzymatic treatment did not have any effect in pure ICG 
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fluorescence as expected. 
A B  
Fig. 3.2 (A) FMT Fluorescence change of ICG-MESL after adding 10 µl 1.0 U/ml SMase. (B) 
FMT Fluorescence change of pure ICG after adding 10 µl 1.0 U/ml SMase. Columns denote 
the mean ± SD, **, p< 0.01, Independent-Sample T-Test. 
 
3.1.3 Fluorescence change of ICG-MESL with SMase and AMF 
Synergistic effects of SMase and AMF treatment in ICG-MESL (0.030 mg/ml) were studied. 
The fluorescence signal increases both after adding enzyme and additional AMF. AMF could 
significantly increase the FMT fluorescence compared with only adding SMase in some 
groups (Fig. 3.3). Some synergistic effect could be seen when higher SMase activities were 
used 
 
Fig. 3.3 Percentage increase of FMT fluorescence after adding SMase without /with AMF. 
Columns denote the mean ± SD, *, P < 0.05, Paired-Samples T-Test. 
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3.2 In vitro characterization: ASMase activity as a cell stress indicator in HNSCC lines 
3.2.1 ASMase activity of SCC9 and UDSCC2 after irradiation 
ASMase activity after irradiation caused stress was measured using Amplex Red 
Sphingomyelinase Assay Kit. Quantitative calculation of the SMase release was done 
according to the standard curve. The SMase release was corrected with control group (without 
irradiation). High doses (24 Gy, 36 Gy) of irradiation could trigger significantly more 
ASMase in supernatant than low doses (12 Gy) in SCC9 (Fig. 3.4A). Dose response of SMase 
release was observed after different intensity of irradiation in UDSCC2 (Fig. 3.4B). UDSCC2 
are significantly more sensitive than SCC9 in trigging the ASMase activity in the high doses 
of irradiation (Fig. 3.4C). Cells viability was measured by MTT assay 6 hours after irradiation. 
No significant differences were observed among different doses of irradiation or different cell 
lines. (p≥ 0.05, Independent-Sample T-Test) (Fig. 3.4D).  
A  B  
Fig. 3.4 (A) SMase increase of SCC9 after different doses of irradiation. (B) SMase increase 
of UDSCC2 after different doses of irradiation. Columns denote the mean ± SD, **, p< 0.01, 
Independent-Sample T-Test. 
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C  D  
Fig. 3.4 (C) Comparison of SMase increase in SCC9 and UDSCC2 after different doses of 
irradiation. Columns denote the mean ± SD, * p< 0.05, Independent-Sample T-Test. (D) Cells 
viability of SCC9 and UDSCC2 after different doses of irradiation (measure in 6 hours later). 
Columns denote the mean ± SD, p≥ 0.05, Independent-Sample T-Test. 
 
3.2.2 ASMase activity of Keratinocyte after irradiation 
We wanted to study irradiation response of normal keratinocyte grown from patient samples. 
The ASMase activity in Keratinocyte was studied to compare the regular tissue cells with 
carcinoma cells. ASMase activity of Keratinocyte is significantly lower than in both SCC9 
and UDSCC2 cells after 24 Gy irradiation (Fig. 3.5A). Cells viability was measured with 
MTT assay 6 hours after irradiation. No significant differences were observed with different 
cell lines after 24 Gy irradiation. (p≥0.05, Independent-Sample T-Test; Fig. 3.5B). 
A  B  
Fig. 3.5 ASMase activity (A) and cells viability (B) of Keratinocyte, SCC9 and UDSCC2 
after 24 Gy irradiation. Columns denote the mean ± SD, *, p< 0.05, **, p< 0.01, 
Independent-Sample T-Test.  
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3.2.3 Cisplatin release from Cisplatin-MESL after irradiation (SCC9) 
While we have shown that the radiation increases ASMase activity in SCC9 and UDSCC2 
cell media, we wanted to study if this enzymatic activity enough to cause drug release from 
Cisplatin-MESL like we have previously shown in our vitro studies. The experiment shows 
that Cisplatin could be released from Cisplatin-MESL and that the release is dose-dependent 
(Fig. 3.6A).  
A  
Fig. 3.6 (A) Cisplatin release from Cisplatin-MESL after different doses radiotherapy. (SCC9). 
**, p< 0.01, Independent -Sample T-Test.  
 
3.2.4 ASMase inhibition study in SCC9 after irradiation 
While we have shown that the ASMase activities enough to cause drug release from 
Cisplatin-MESL after irradiation, we wanted to extra proof if enzymatic activities are 
necessary to cause drug release. Desipramine, SMase inhibitor, inhibits ASMase activity of 
SCC9 after 24 Gy irradiation. UDSCC2 was not tested yet. ASMase activity in desipramine 
group is significant lower than in normal treated group (Fig. 3.7A). Desipramine, SMase 
inhibitor, not only inhibits the ASMase activity after irradiation, also inhibits the release of 
cisplatin from Cisplatin-MESL after 24 Gy irradiation (Fig. 3.7B).  
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A  B  
Fig. 3.7 (A) Desipramine, SMase inhibitor, inhibits ASMase activity in SCC9 after 24 Gy 
irradiation. Columns denote the mean ± SD, p≥ 0.05, Independent-Sample T-Test. (B) 
Cisplatin release from Cisplatin-MESL of desipramine treated SCC9 compare with control 
groups after 24 Gy radiotherapy. Columns denote the mean ± SD, **, p< 0.01, 
Independent-Sample T-Test. 
 
3.2.5 ASMase activity as a cell stress indicator after cisplatin treatment 
While it has shown previously that irradiation treatment increases ASMase activities, we 
wanted to study how other stress inducer, cisplatin treatment, effects SCC9 and UDSCC2 
cells. ASMase activity was measured by Amplex Red Sphingomyelinase Assay Kit. 
Quantitative calculation of the ASMase activity was calculated from standard curve which 
was done analyzing fluorescence of the known SMase activities. The SMase activity is 
background corrected with control group. SMase activity of UDSCC2 showed marked 
significance as well a dose response of cisplatin in 48 hours treatment. Significant increases 
of SMase activity and decrease of cell viability were observed with treatment time of higher 
dose cisplatin. Similar phenomenon was not seen in the SCC9 (Fig. 3.7). 
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A  B  
C  D  
Fig. 3.7 (A) ASMase activation after different concentration of cisplatin treatment (0.1 µM/ml, 
1.0 µM/ml and 10 µM/ml) for different times (12 hours, 24 hours and 48 hours) in UDSCC2. 
(B) Cells viability after cisplatin treatment for different times. Columns and lines denote the 
mean ± SD**, p< 0.01, Independent-Sample T-Test. (C) UDSCC2 Cells before cisplatin 
treatment. (D) Cells after 10 µM/ml cisplatin treatment for 48 hours (Phase contrast 
microscope × 20). 
 
E  F  
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G  H  
Fig. 3.7 (E) ASMase activation after different concentration of cisplatin treatment (0.1 µM/ml, 
1.0 µM/ml and 10 µM/ml) for different times (12 hours, 24 hours and 48 hours) in SCC9. (F) 
Cells viability after cisplatin treatment for different times. (G) SCC9 Cells before cisplatin 
treatment. (H) Cells after 10 µM/ml cisplatin treatment for 48 hours (Phase contrast 
microscope × 20).  
 
3.3 ASMase activity of HNSCC and muscle in mouse 
We wanted to study whether SCC9 tumor grown in mice has higher SMase activity compared 
to muscle and if MESL system can be used in vivo in imaging of tumor / tumor targeting. The 
tumor tissues from ten mice were studied. Tumor size was measured by the ultrasound (Fig. 
3.8A). MESL/ICG could be seen accumulated in the tumor area after intravenous injection of 
ICG-MESL from caudal (Fig. 3.8C). ASMase activity was measured using Amplex Red 
Sphingomyelinase Assay Kit. Quantitative calculation of the SMase activity was analyzed 
against the standard curve. Tumors have significantly higher ASMase activity compared to the 
control tissue back leg muscle (Fig. 3.8D).  
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A     
B  C  
Fig. 3.8 (A) 3-Dimensional image reconstruction of mouse carcinoma was simulated by the 
ultrasound. (B) Carcinoma of the mouse by visual inspection. (B) Operation-microscope 
image of a nude mouse with mouth floor tumors. The skin was removed in the neck area for a 
better representation of the tumor. (C) A visual marker of the tumor is possible using a 
fluorescence filter after intravenous injection of ICG-MESL from caudal. 
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Fig. 3.8 (D) ASMase activity of tumor and muscle in 10 mice (Individual and mean value of 
ten mice). Tumor has significantly higher ASMase activation than muscle. **, p< 0.01, 
Paired-Samples T-Test. 
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4. Discussion of results 
4.1 Optical properties of environment sensing ICG-MESL probe  
ICG is one of the only clinically approved contrast agents that have been used for several 
decades. ICG is widely used contrast agent but there are limitations like its low stability, rapid 
degradation in aqueous environments and its strong binding to serum albumin that leads to a 
degradation or fluctuation of the optical signal (Mordon, et al., 2013; Saxena, et al., 2003). 
Previously have been reports of developed liposomes with ICG, encapsulated or adsorbed to 
lipid membrane with various compositions and physiochemical properties to overcome these 
limitations (Steven, et al., 2010; Jeong, et al., 2013). However, most of these liposomes with 
varying compositions containing ICG were prepared without a full understanding of the 
interactions between ICG and lipids. ICG can physically interact with phospholipids in the 
liposome membrane and modify the stability of and quantum yield of ICG as well as the 
structure and stability of the lipid membrane. ICG may also be encapsulated in the aqueous 
compartment of liposome. These properties and variations could profoundly impact optical 
NIR imaging quality. (Kraft and Ho, 2014; Beziere, et al., 2014). In our liposomal in vitro 
experiments, we wanted to study if free ICG and liposomal ICG can be differentiate by 
fluorescence. ICG-MESL demonstrates significant fluorescence enhancement compared to 
free ICG. This fluorescence enhancement may be related to insertion of ICG within the 
hydrophobic compartment of the lipid bilayer. The ICG is known to be photos table in 
hydrophobic organic microenvironments. The fluorescence of pure ICG decreases in high 
concentration which is probably because of fluorescence quenching (self-quenching) (Kraft 
and Ho, 2014; Beziere, et al., 2014). 
The purpose of our in vitro study was to find ICG concentration loaded in MESL that exhibits 
both maximal fluorescence intensity and minimal self-quenching. From our concentration 
studies we decided to use 0,030 mg/ml ICG in our future studies. 
One of the main components of MESL liposomes, sphingomyelin, is converted to ceramide 
by SMase. The formed ceramide destabilizes the bilayer structure of the liposomes (Megha 
and London, 2004; Rebillard, et al., 2007; Ira and Johnston, 2008; López-Montero, et al., 
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2005). This may contribute to ICG redistribution and leakage of ICG from liposome. ICG 
fluorescence may also be increased after SMase treatment because the enzyme makes 
liposomes leakier and ICG is released and redistribution, which change the environment for 
ICG (self-quenching decreased when ICG free). MESL containing 0.50 mg/ml of ICG reveals 
optimal fluorescence increase after enzymatic reaction in our research. Nevertheless, the 
precise mechanism of fluorescence enhancement after reaction with enzyme is not clear. 
ICG-MESL prepared by adding Fe3O4 nanoparticles could produce an additive response if an 
external magnetic field would also add. This would probably be due to Brownian motion. 
Addition AMF adds effects on the ICG fluorescence signal when used together with ASMase 
in MESL. We could see synergistic increase in our vitro studies when both AMF and enzyme 
was used. Similar effect has also seen previously with different methods in other research 
group. The interaction between a magnetic field and the ferromagnetic moments induces 
magneto mechanical forces, which may be employed to change the structure of the liposome 
and increase encapsulated substance release (Behrens and Appel, 2016). Here we propose that 
this phenomenon can be utilized in cisplatin delivery and release in MESL. 
4.2 ASMase activity as a cell stress indicator after irradiation in HNSCC lines 
DNA double helix damaging has been considered as the main deleterious effects of irradiation 
for decades. Signals alterations on cellular membranes are also identified having role in 
radiation-induced apoptosis. SM degradation pathway causes SM hydrolysis on the cell 
membrane and subsequent ceramide generation which can participate the cellular signaling of 
programmed cell death. (Hannun and Obeid, 2008; Grassme et al., 2001; Adada, et al., 2016). 
Here we have shown first time the difference in the radiation response of ASMase secretion of 
SCC cells and papilloma infected UDSCC cells. 
Transitory increase of ceramide has been observed within minutes after irradiation exposure 
as a consequence of DNA damage independent ASMase activation (Vit and Rosselli, 2003; 
Wang, et al., 2015). How they form ASMase after irradiation and what are the different levels 
of ASMase in SCC9 and UDSCC2 were evaluated in our study. Medium supernatant without 
cells was collected immediately after irradiation to measure the secreted ASMase activity.  
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MTT investigation suggested that all the cells (6 hours after irradiation) were alive. This 
means that the ASMase activity we measured in medium was mainly secretory ASMase rather 
than lysosome ASMase released from death cells.  
Dose response for the ASMase activity by increased irradiation doses was observed both in 
SCC9 and UDSCC2 cell lines. ASMase activity induced by irradiation in UDSCC2 was 
significantly higher than that in SCC9, which is in accordance with the clinical observation 
that HPV positive carcinoma better respond to irradiation than HPV negative carcinoma (Ang 
and Sturgis, 2012; Marcu, 2016). The molecular mechanisms are at present still incompletely 
understood. One hypothesis for enhanced responsiveness of HPV positive HNSCC to 
radiotherapy might be caused by cell cycle dysregulation and impaired DNA repair (Arenz, et 
al., 2014). Our data supposes that sphingolipid ASMase / ceramide signaling pathway 
probably play an important role in HPV-associated HNSCC after radiotherapy as well. The 
differences of ASMase activation possibly lead tumors individualized treatment of 
HPV-associated HNSCC with MESL Nanoparticle carrier system in future. 
Keratinocyte was chosen to compare the effect of radiation on normal tissue and cancer 
tissues. It has previously shown that ASMase activation and ceramide generation associated 
apoptosis can be induced by Ultraviolet B (UVB) radiation in human Keratinocyte (Magnoni, 
et al., 2002). No studies have yet focused activation of ASMase in Keratinocyte induced by 
irradiation, as well as compared the differences of ASMase levels to HNSCC lines. Our 
research data showed that exposure to irradiation also result in rapid generation of ASMase 
activity in Keratinocyte, although the ASMase activity was significantly lower than HNSCC 
lines. This data still needs to be repeated before any assumptions can be made. 
In model liposomal membranes it has previously been shown that bacterial SMase can make 
SM containing liposomes leakier (Begoña Ruiz-Argüello, et al., 1998 and 1999). This makes 
MESL an interesting potential candidate for triggered drug release. ASMase secreted from 
SCC9 and UDSCC2 in quantities that are sufficient to release the payload of cisplatin. The 
dose responsive release of cisplatin from MESL was observed after increased heavy 
irradiation in SCC9 cells. SMase inhibitor, desipramine, which inhibits the ASMase 
maturation process and thus decrease its formation (Elojeimy, et al., 2006), cause drop in 
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ASMase activity after irradiation in our studies thus proving ASMase indeed is part of the 
process. In addition, desipramine pretreatment inhibits the cisplatin release from MESL after 
radiation. These results reveal that ASMase is needed in the payload cisplatin release process 
in MESL. 
4.3 ASMase activity as a cell stress indicator after cisplatin treatment in HNSCC lines 
The chemotherapeutic agent cisplatin has been cornerstones in the treatment of solid tumor. 
Once classically considered as a nuclear DNA damaging agent, cisplatin has been regarded to 
induce apoptosis through plasma membrane disruption in recent studies (Maurmann et al., 
2015). ASMase emerges as key enzyme which induces a critical step for ceramide generation. 
Pro-apoptotic receptors, including FAS death receptor pathways, could be induced through 
activation of ceramide (Noda et al., 2001; Rebillard, et al., 2006 and 2007). 
MTT test was preformed simultaneously after cisplatin treatment. We could also show a clear 
dose-response relationship between the cisplatin concentration and the activation of ASMase 
after 48 hours’ treatment in UDSCC2 cells. Negative correlation has been observed between 
the cells viability and ASMase activity. It is hard to distinguish the increase of ASMase 
activity from extra nuclear (secretory ASMase) or released form dead cells (lysosome 
ASMase). We suppose that overwhelming majority of ASMase activity was from the 
lysosome ASMase of dead cells for their positive correlation. Further experimental proof for 
this hypothesis needs to be characterized. Regardless ASMase activity in supernatant from 
extra nuclear or lysosome, we suppose that ASMase activity induced by cisplatin treatment 
should be performed to amplify the release of payload cisplatin from MESL. 
Our data shows that UDSCC2 better respond to cisplatin than SCC9, which is in accordance 
to the other vitro studies that higher sensitivity of the group of HPV positive cells to Cisplatin 
(Ziemann et al., 2015). Whether the invasive growth level or treatment sensitivity differences 
of these two HNSCC lines would affect the ASMase activity after cisplatin treatment remains 
further research. 
In order to evaluate the secretory ASMase of extranuclear induced by cisplatin, temporary 
increase of ASMase activity in the supernatant was measured after short time of cisplatin 
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treatment ranging from 1 minutes to 60 minutes. Nevertheless, activation trend hardly could 
be observed in the result. We suppose that such amount of ASMase activation induced by 
short time treatment of cisplatin was too small to be measured or might be disordered by other 
cellular stress induced ASMase. The experimental design was imperfect to measure the short 
time of cisplatin treatment and need to be improved in the future study. Other methods like 
flow cytometry or immunoblotting might serve better for these studies.  
4.4 In Vivo characterization: aSMase activity of HNSCC and muscle in mouse 
Of the several studies generically reporting ASMase induced ceramide accumulation 
commonly observed to induce apoptosis in some specific cell lines, rare research has 
addressed the exactly ASMase activity in any cell lines. To the best of our knowledge, our 
study is the first report to evaluate the secretory ASMase activity of SCC9 tumor grown in 
mice into the comparison with muscle. Our study has revealed an almost two-fold higher of 
ASMase activity among tumor than muscles in mice. Similar results we have also observed in 
samples from HNSCC cancer patients (data are not shown here). Whether the extremely high 
ASMase activity of tumor could enzymatic release more payload cisplatin from MESL in 
target tissue remain to be further corroborated in vivo.  
The imaging of ICG has been applied to intraoperative identification of several solid tumors 
and sentinel lymph node detection. Nevertheless, it also shows several drawbacks, which limit 
its clinical application (Jarmo et al., 2012; Kraft and Ho, 2014; Desmettre et al., 2000). The 
fluorescence image of SCC9 tumor in mice has been observed using a fluorescence filter after 
intravenous injection of ICG-MESL from caudal. Whether ICG-MESL could overcome the 
limitation of ICG and perform the promising advantages as our vitro study in mice remain to 
be well characterized. 
 
 
 
 
 
37 
 
 
5. Conclusion 
Magneto-enzymatic sensitive liposome (MESL) carrier system combines the stress 
related enzyme, acid sphingomyelinase (ASMase), and alternating magnetic field (AMF) 
treatment together. Local enzymatically activated release will be triggered by ASMase, 
which is produced in cancer tissue or induced by cellular stress through radiation, 
hypoxia or chemical drugs. Iron particles in the lipid bilayer membrane of the liposome 
will amplify activation through alternating magnetic field by harmless magnetic fields. 
These two activation mechanisms enable locally controlled release. Investigation of the 
combined opening power of SMase and AMF, the efficiency of Indocyanine Green (ICG) 
for fluorescent labeling and cisplatin as a chemotherapeutic agent for treatment of MESL 
nanoparticle carrier was studied in vitro assay.  
The fluorescent signal of ICG-MESL in blood shows significantly higher than pure ICG. 
ASMase has effects on the fluorescent signal of ICG-MESL that increases with AMF. 
However, results obtained from vitro experimental model cannot represent the fluorescent 
signal in vivo. Blood circulation, macrophage phagocytosis and metabolism of the MESL 
in vivo should be considered in the further research.  
Endogenous ASMase activation on extracellular can be induced by cellular stress through 
irradiation. The dose response for the ASMase activities by increased radiation dose has 
be observed in both SCC9 and UDSCC2 cells. ASMase activity in UDSCC2 was 
significantly higher than that in SCC9, which is in accordance with the clinical 
observation that HPV positive carcinoma better respond to irradiation than HPV negative 
carcinoma. Endogenous ASMase activation is needed and sufficient to release the 
payload of cisplatin from MESL. The dose response for the liposomal cisplatin release by 
increased radiation doses and increased ASMase activities was observed. 
Temporary increase of ASMase activity on extracellular induced by cisplatin is hard to be 
measured. Nevertheless, dose-response has been observed between long treatment time 
and ASMase activity in high dose concentration of cisplatin (10 µM/ml). Negative 
correlation has been observed between the cells viability and ASMase activity in long 
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time cisplatin treatment. We suppose that majority of ASMase activity is from the 
lysosome of dead cells for their positive correlation. Regardless ASMase activity from 
extracellular or lysosome, we suppose that ASMase activity induced by cisplatin 
treatment could be performed to amplify the release of payload cisplatin from MESL. 
Further experimental proof for this hypothesis needs to be characterized. 
Mouse model of HNSCC has been generated by our research group. Results revealed an 
almost two-fold higher of ASMase activity among tumor than muscles in mice. Whether 
the extremely high ASMase activity of tumor could enzymatic release more payload 
cisplatin from MESL in target tissue remain to be further corroborated in vivo. 
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7. Appendices 
7.1 Fluorescence of ICG-MESL and pure ICG in blood 
FMT fluorescence of different concentration of Pure - ICG 
mg/ml Series 1 Series 2 Series 3 
0.330  2071.08  2080.38  2137.49  1866.93  1821.68  1850.78  2239.95  1990.69  1971.78  
0.165 2380.39  2418.14  2353.52  2050.16  2203.25  2179.65  2349.68  2185.41  2194.67  
0.066 1596.75  1559.02  1525.28  1388.61  1406.75  1515.20  1722.70  1547.94  1639.51  
0.033 618.29  603.83  599.71  796.55  829.38  879.61  998.08  798.62  838.07  
          
          FMT fluorescence of different concentration of ICG - MESL 
mg/ml Series 1 Series 2 Series 3 
0.330  4172.55  4450.59  4635.03  5072.46  4955.40  4954.15  5584.09  5437.35  5519.97  
0.165 2727.81  2535.27  2977.06  3536.45  3609.60  3533.35  4094.87  3877.10  4045.00  
0.066 2368.54  2102.36  2344.87  2365.44  2328.82  2317.71  2489.97  2469.98  2523.97  
0.033 1796.65  1672.20  1752.08  2279.75  2268.79  2227.96  2162.77  2153.63  2157.35  
          
          FMT fluorescence of different concentration of Pure - ICG & ICG - MESL  
mg/ml 
Pure - ICG ICG - MESL 
p. value  
MEAN SD MEAN SD 
0.330  2003.4182  136.6902  4975.7316  547.4359  7.70×10-12 
0.165 2257.2075  120.4380  3437.3894  638.3367  1.52×10-05 
0.066 1544.6391  100.8538  2367.9632  114.4774  6.67×10-11 
0.033 773.5712  145.6172  2052.3528  274.9084  2.58×10-10 
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7.2 Fluorescence change of ICG-MESL and pure ICG with SMase 
FMT fluorescence (MEAN) of Pure - ICG after adding SMase 
mg/ml Without SMase With SMase 
0.006  1772.78  2044.02  1841.57  1759.46  2073.81  2093.22  
0.015  3471.82  3198.57  3490.71  3100.15  3466.50  3484.45  
0.030  3056.04  3273.60  3307.40  3186.10  3486.80  3242.27  
       
mg/ml 
Without SMase With SMase 
p. value  
MEAN SD MEAN SD 
0.006  1886.125 141.0018 1975.498 187.3455 0.5452  
0.015  3387.033 163.4892 3350.366 216.8771 0.8266  
0.030  3212.345 136.4115 3305.058 159.8808 0.4874  
       FMT fluorescence (MEAN) of ICG - MESL after adding SMase 
mg/ml Without SMase With SMase 
0.006  4498.40  4279.78  4303.23  4045.29  4004.15  4323.58  
0.015  4626.92  5089.97  4892.41  4511.15  5209.17  5346.25  
0.030  5452.24  5631.25  5742.27  6815.54  6868.09  6639.36  
       
mg/ml 
Without SMase With SMase 
p. value  
MEAN SD MEAN SD 
0.006  4360.468 120.0226 4124.337 173.7693 0.1249  
0.015  4869.769 232.3524 5022.192 447.848 0.6284  
0.030  5608.585 146.3391 6774.332 119.8047 0.0004  
7.3 Fluorescence % increase of ICG-MESL with SMase and AMF 
SMase U/ml Serie1 Serie2 Serie3 MEAN SD 
 +SMase 
 +20min 
0.364 0.322  0.263  0.140  0.169  0.104  
0.727 0.276  0.136  0.025  0.189  0.216  
1.091 0.098  0.172  0.103  0.208  0.130  
1.455 0.319  0.123  0.044  0.215  0.163  
 +SMase 
 +20min AFM 
0.364 0.469  0.249  0.285  0.255  0.190  
0.727 0.181  0.240  0.111  0.288  0.305  
1.091 0.222  0.251  0.200  0.295  0.092  
1.455 0.612  0.346  0.565  0.344  0.209  
       SMase  +SMase   +SMase & AFM 
p. value  
 U/ml MEAN SD MEAN SD 
0.364 0.169  0.104  0.255  0.190  0.346  
0.727 0.189  0.216  0.288  0.305  0.718  
1.091 0.208  0.130  0.295  0.092  0.024  
1.455 0.215  0.163  0.344  0.209  0.040  
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7.4 ASMase activity after irradiation 
Schematic of 96-wells plate 
 
 
<>  1 2 3 4 5 6 7 8 9 10 11 12 
A 0 Gy - 1 0 Gy - 2 0 Gy - 3       
B 12 Gy - 1 12 Gy - 2 12 Gy - 3 Reaction buffer   
C 24 Gy - 1 24 Gy - 2 24 Gy - 3 0.0004 U   
D 36 Gy - 1 36 Gy - 2 36 Gy - 3 0.002 U   
E                   0.004 U   
F                   0.01 U   
G                   0.04 U   
H                         
Original data of absorbance value (SCC9) 
<>  1 2 3 4 5 6 7 8 9 10 11 12 
A 24534 23197 24301 24728 22774 23478 24731 24396 26200 441 439 452 
B 34517 32461 35596 36509 33877 35752 38053 37911 39274 23451 23119 448 
C 43893 42704 44704 48607 45816 47249 43952 43849 45033 15175 15936 479 
D 47250 35483 47743 46894 46002 49128 50478 48451 50801 16679 16947 449 
E 441 394 496 435 454 464 483 428 426 22906 21756 450 
F 471 439 428 471 514 389 453 467 439 29037 29963 426 
G 496 478 424 464 468 449 414 521 407 50793 49167 445 
H 447 413 439 440 521 442 445 462 403 441 418 498 
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Standard Curve (SCC9) 
aSMase (U) Absorbance Value Average Std 
0.04 50793 49167 49980 1149.75563 
0.01 29037 29963 29500 654.780879 
0.004 22906 21756 22331 813.172798 
0.002 16679 16947 16813 189.504617 
0.0004 15175 15936 15555.5 538.10826 
 
 
 
ASMase release (calculate by standard curve) (SCC9) 
0 Gy 0.009 0.007 0.008 0.009 0.006 0.007 0.009 0.008 0.011 
12 Gy 0.020 0.018 0.022 0.023 0.020 0.022 0.025 0.024 0.026 
24 Gy 0.032 0.030 0.033 0.037 0.034 0.036 0.032 0.032 0.033 
36 Gy 0.036 0.022 0.036 0.035 0.034 0.038 0.039 0.037 0.040 
 
ASMase release (compare to the control group) (SCC9) 
12 Gy 0.012 0.010 0.014 0.015 0.011 0.014 0.016 0.016 0.018 
24 Gy 0.023 0.022 0.024 0.029 0.026 0.027 0.023 0.023 0.025 
36 Gy 0.027 0.013 0.028 0.027 0.026 0.030 0.031 0.029 0.032 
 
Average and std value (SCC9) 
Radiation MEAN SEM 
 
P. value  
12 Gy 0.0140  0.0026  
 
12 Gy Vs. 24 Gy 5.57×10-8 
24 Gy 0.0248  0.0022  
 
12 Gy Vs. 36 Gy 7.86×10-6 
36 Gy 0.0270  0.0054  
 
24 Gy Vs. 36 Gy 0.284 
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Schematic of 96-wells plate 
 
 
<>  1 2 3 4 5 6 7 8 9 10 11 12 
A 0 Gy - 1 0 Gy - 2 0 Gy - 3       
B 12 Gy - 1 12 Gy - 2 12 Gy - 3 Reaction buffer   
C 24 Gy - 1 24 Gy - 2 24 Gy - 3 0.0004 U   
D 36 Gy - 1 36 Gy - 2 36 Gy - 3 0.002 U   
E                   0.004 U   
F                   0.01 U   
G                   0.04 U   
H                         
Original data of absorbance value (UDSCC2) 
<>  1 2 3 4 5 6 7 8 9 10 11 12 
A 22039 22877 23227 24072 23837 24688 24383 24008 23939 323 319 337 
B 32907 33342 34996 36293 34509 35346 35178 34310 36044 20832 21499 308 
C 45410 45744 46772 45582 43110 44681 46408 45448 47031 14292 14597 334 
D 46113 47095 48815 54767 53994 54185 57110 55379 Overflow 15787 15737 314 
E 303 360 322 370 343 316 330 354 317 20647 20310 304 
F 306 334 322 329 314 346 343 328 341 27923 26252 339 
G 354 334 343 288 351 324 323 354 295 44429 46042 288 
H 309 311 347 342 332 327 330 338 305 317 307 334 
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Standard Curve (UDSCC2) 
aSMase （U） Absorbance Value Average Std 
0.04 44429 45235.5  45235.5  1140.6 
0.01 27923 27087.5  27087.5 1181.6 
0.004 20647 20478.5  20478.5 238.3 
0.002 15787 15762.0  15672.0 35.4 
0.0004 14292 14444.5  14444.5 215.7 
 
 
ASMase release (calculate by standard curve) (UDSCC2) 
0 Gy 0.008 0.009 0.009 0.011 0.010 0.011 0.011 0.010 0.010 
12 Gy 0.022 0.023 0.025 0.027 0.025 0.026 0.025 0.024 0.027 
24 Gy 0.039 0.040 0.041 0.039 0.036 0.038 0.040 0.039 0.041 
36 Gy 0.040 0.041 0.044 0.052 0.051 0.051 0.055 0.052 
 
ASMase release (compare to the control group) (UDSCC2) 
12 Gy 0.012 0.013 0.015 0.017 0.014 0.016 0.015 0.014 0.017 
24 Gy 0.029 0.029 0.031 0.029 0.026 0.028 0.030 0.029 0.031 
36 Gy 0.030 0.031 0.034 0.042 0.040 0.041 0.045 0.042 
 
MEAN, SEM and P. value (UDSCC2) 
Radiation MEAN SEM 
 
P. value 
12 Gy 0.0148 0.0015 
 
12Gy Vs. 24 Gy 1.12×10-12 
24 Gy 0.0292 0.0016 
 
12Gy Vs. 36 Gy 4.11×10-9 
36 Gy 0.0381 0.0056 
 
24Gy Vs. 36 Gy 3.80×10-4 
Compare of aSMase activity of SCC9 and UDSCC2 after irradiation 
Radiation 
SCC9 UDSCC2 
P. value 
MEAN SEM MEAN SEM 
12 Gy 0.0140 0.0026 0.0148 0.0015 0.420413 
24 Gy 0.0248 0.0022 0.0292 0.0016 0.000168 
36 Gy 0.0270 0.0054 0.0381 0.0056 0.000889 
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7.5 ASMase activity of Keratinocyte and SCC9 after 24 Gy irradiation 
 
Schematic of 96-wells plate (Keratinocyte & SCC9) 
<> 1 2 3 4 5 6 7 8 9 
A SCC9 0 Gy -1 SCC9 0 Gy -2 SCC9 0 Gy -3 
B SCC9 24 Gy -1 SCC9 24 Gy -2 SCC9 24 Gy -3 
C  keratinocyte 0 Gy -1  keratinocyte 0 Gy -2  keratinocyte 0 Gy -3 
D  Keratinocyte 24 Gy -1  Keratinocyte 24 Gy -2  Keratinocyte 24 Gy -3 
Original data of absorbance value (Keratinocyte & SCC9) 
<> 1 2 3 4 5 6 7 8 9 
A 16773 17533 17095 20392 20192 19863 20088 21078 20093 
B 45827 45444 46378 46753 42392 41568 42923 41419 47728 
C 23121 21828 21090 25505 23447 26121 21823 22223 23413 
D 34931 36103 35488 34818 34699 31566 30720 32700 32495 
ASMase release (calculate by standard curve) (Keratinocyte & SCC9) 
<> 1 2 3 4 5 6 7 8 9 
A 0.0082  0.0089  0.0085  0.0118  0.0116  0.0112  0.0115  0.0124  0.0115  
B 0.0369  0.0366  0.0375  0.0379  0.0335  0.0327  0.0341  0.0326  0.0388  
C 0.0145  0.0132  0.0125  0.0168  0.0148  0.0174  0.0132  0.0136  0.0148  
D 0.0262  0.0273  0.0267  0.0260  0.0259  0.0228  0.0220  0.0239  0.0237  
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Compare with each control group 
<> Average Std 
SCC9 24 GY 0.0250  0.0024  
Keratinocyte 24 GY 0.0104  0.0017  
 
Date of UDSCC2 from another plate 
<> Average Std 
UDSCC2 24 GY 0.0290  0.0020  
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7.6 MTT test: 6 hours after different irradiation 
A  
B  
Schematic of 96-wells plate for the MTT test after irradiation. (A) Standard curve group; (B) 
Experiment group (1-3 lines) and bland control group (4th line) for one dose of irradiation.   
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Standard Curve 
(SCC9)
Concentration
1 10 100
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
Graph#1
y = ( (A - D)/(1 + (x/C)^B ) ) + D: A B C D R^2
Std (Standards: Concentration vs MeanValue) -0,068 0,667 99,063 1,937 0,999  
Absorbance Value (SCC9) 
12 Gy 24 Gy 36 Gy 
0.956  0.971  0.948  0.980  0.947  1.018  1.001  0.989  1.014  
0.976  0.793  0.928  0.858  0.747  0.962  1.021  0.850  0.905  
0.969  0.893  0.931  0.974  0.873  0.916  1.004  0.850  0.877  
0.977  0.897  0.937  0.934  0.884  0.912  1.013  0.779  0.855  
0.978  0.902  0.895  0.937  0.932  0.987  0.958  0.829  0.975  
0.938  0.992  0.744  0.986  0.888  0.963  1.025  0.831  0.926  
1.017  0.871  0.906  1.013  0.807  0.965  1.098  0.852  0.955  
1.037  0.992  1.007  1.059  0.982  0.924  1.026  1.012  1.044  
 
Cells viability (% of Control) (SCC9) 
12 Gy 24 Gy 36 Gy 
97.09% 95.15% 98.11% 94.02% 98.26% 89.37% 91.47% 92.86% 89.86% 
94.50% 120.79% 100.80% 110.65% 128.69% 96.38% 89.02% 111.90% 103.95% 
95.42% 105.58% 100.34% 94.75% 108.46% 102.37% 91.11% 111.79% 107.80% 
94.46% 105.03% 99.55% 99.97% 106.90% 102.93% 89.94% 123.06% 111.12% 
94.34% 104.28% 105.24% 99.57% 100.25% 93.18% 96.81% 115.01% 94.71% 
99.41% 92.49% 129.11% 93.26% 106.23% 96.24% 88.60% 114.74% 101.05% 
89.55% 108.67% 103.82% 90.04% 118.55% 95.98% 80.20% 111.55% 97.18% 
87.14% 92.49% 90.76% 84.58% 93.77% 101.36% 88.46% 90.12% 86.31% 
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Standard Curve (UDSCC2) 
Concentration
0 10 20 30 40 50 60 70 80 90 100
0
0,1
0,2
0,3
0,4
0,5
0,6
Graph#1
y = A + Bx: A B R^2
Std (Standards: Concentration vs MeanValue) 0,012 0,006 0,975   
Absorbance Value (UDSCC2) 
12 Gy 24 Gy 36 Gy 
0.713 0.718 0.693 0.656 0.636 0.605 0.641 0.630 0.626 
0.713 0.668 0.738 0.688 0.615 0.580 0.708 0.603 0.585 
0.656 0.603 0.678 0.680 0.615 0.559 0.659 0.542 0.553 
0.730 0.619 0.654 0.637 0.592 0.579 0.669 0.545 0.512 
0.688 0.652 0.656 0.657 0.548 0.546 0.680 0.661 0.502 
0.699 0.723 0.676 0.674 0.624 0.636 0.688 0.641 0.583 
0.667 0.688 0.598 0.674 0.677 0.625 0.703 0.693 0.637 
0.677 0.637 0.668 0.744 0.672 0.702 0.749 0.713 0.652 
 
Cells viability (% of Control) (UDSCC2) 
12 Gy 24 Gy 36 Gy 
115.81% 116.75% 112.50% 106.31% 102.98% 97.88% 103.77% 102.05% 101.32% 
115.76% 108.35% 119.98% 111.71% 99.55% 93.68% 115.05% 97.57% 94.54% 
106.38% 97.43% 110.00% 110.31% 99.43% 90.25% 106.85% 87.27% 89.15% 
118.68% 100.18% 105.93% 103.20% 95.71% 93.48% 108.52% 87.82% 82.29% 
111.66% 105.73% 106.31% 106.53% 88.28% 88.00% 110.30% 107.12% 80.62% 
113.46% 117.50% 109.63% 109.33% 101.03% 103.03% 111.59% 103.79% 94.14% 
108.15% 111.66% 96.61% 109.31% 109.80% 101.10% 114.12% 112.44% 103.12% 
109.81% 103.18% 108.35% 121.06% 109.06% 114.01% 121.82% 115.82% 105.62% 
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Standard Curve (Keratinocyte) 
Concentration
0 10 20 30 40 50 60 70 80 90 100
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
Graph#1
y = A + Bx: A B R^2
Std (Standards: Concentration vs MeanValue) -0,033 0,01 0,989  
Absorbance Value (Keratinocyte) 
Standard curve 24 Gy 
0.928  0.999  1.001  0.938  0.913  0.937  
0.563  0.535  0.467  0.959  0.951  0.928  
0.156  0.125  0.169  0.862  0.896  0.951  
0.076  0.070  0.068  0.964  0.844  0.944  
0.042  0.029  0.030  0.873  0.967  0.924  
0.020  0.017  0.019  0.900  0.868  0.915  
0.011  0.007  0.012  0.960  0.949  0.941  
-0.001  -0.001  0.002  0.962  0.934  0.955  
 
Cells viability (% of Control) (Keratinocyte) 
Standard curve 24 Gy 
96.08% 103.20% 103.35% 100.10% 97.57% 100.05% 
59.62% 56.77% 50.02% 102.20% 101.45% 99.12% 
18.92% 15.77% 20.19% 92.51% 95.87% 101.43% 
10.86% 10.30% 10.11% 102.75% 90.66% 100.66% 
7.54% 6.22% 6.30% 93.62% 103.00% 98.74% 
5.26% 5.00% 5.22% 96.31% 93.13% 97.85% 
4.35% 4.02% 4.54% 102.28% 101.17% 100.43% 
3.16% 3.21% 3.52% 102.50% 99.71% 101.80% 
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7.7 ASMase activity after cisplatin treatment 
ASMase activity after cisplatin treatment (12, 24 and 48 hours) (UDSCC2) 
 
Original data of absorbance value (UDSCC2) 
Hour 
Average Std 
Control 0.1 µM 1 µ 10 µM Control 0.1 µM 1 µM 10 µM 
12 39628  39644  39264  38346  888  560  1737  153  
24 37050  37378  37525  39270  451  1322  930  1001  
48 33453  33518  34478  40626  451  1359  893  412  
Background correct of absorbance value (UDSCC2) 
Hour 
Average Std 
0.1 µM 1 µM 10 µM 0.1 µM 
1 
µM 10 µM 
12  16  -364  -1282  560  1737  153  
24  328  475  2220  1322  930  1001  
48  65  1025  7173  1359  893  412  
ASMase release (calculate by standard curve) (UDSCC2) 
Hour 
0.1 µM cisplatin 1 µM 0.1uM cisplatin 10 µM 0.1 µM cisplatin 
MEAN SD MEAN SD MEAN SD 
12 0.0000199  0.0006676  -0.0004333  0.0020694  -0.0015270  0.0001828  
24 0.0003904  0.0015751  0.0005659  0.0011082  0.0026441  0.0011925  
48 0.0000774  0.0016186  0.0012208  0.0010638  0.0085459  0.0004908  
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Original data of absorbance value (SCC9) 
Hour 
Average Std 
Control 0.1 µM 1 µM 10 µM Control 0.1 µM 1 µM 10 µM 
12 43921 42990 43359 42054 1922 1305 587 791 
24 41471 41931 42663 40703 309 1046 522 355 
48 39226 38957 38392 38433 775 1354 278 1541 
Background correct of absorbance value (SCC9) 
Hour 
Average Std 
0.1 µM 1 µM 10 µM 0.1 µM 
1 
µM 10 µM 
12  -931 -562 -1867 1305 587 791 
24  460 1192 -768 1046 522 355 
48  -269 -834 -793 1354 278 1541 
ASMase release (calculate by standard curve) (SCC9) 
Hour 
0.1µM cisplatin 1 µM 0.1 µM cisplatin 10 µM 0.1 µM cisplatin 
MEAN SD MEAN SD MEAN SD 
12 -0.00093 0.001305 -0.00056 0.000587 -0.00187 0.000791 
24 0.00046 0.001046 0.001192 0.000522 -0.00077 0.000355 
48 -0.00027 0.001354 -0.00083 0.000278 -0.00079 0.001541 
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7.8 MTT test: 12, 24 and 48 hours after cisplatin treatment 
 
Standard Curve: UDSCC2 
Concentration
1 10 100
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
Graph#1
y = ( (A - D)/(1 + (x/C)^B ) ) + D: A B C D R^2
Std (Standards: Concentration vs MeanValue) -0,005 0,95 4876,535 31,455 1  
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Schematic of 96-wells plate (UDSCC2) 
<>  
1 2 3 4 5 6 7 8 9 10 11 12 
Standard (%) 48 hours 24 hours 12 hours 
A 100 100 100 control 0.1 10 control 0.1 10 control 0.1 10 
B 50 50 50 control 0.1 10 control 0.1 10 control 0.1 10 
C 25 25 25 control 0.1 10 control 0.1 10 control 0.1 10 
D 12.5 12.5 12.5 control 0.1 10 control 0.1 10 control 0.1 10 
E 6.25 6.25 6.25 control 1 100 control 1 100 control 1 100 
F 3.12 3.12 3.12 control 1 100 control 1 100 control 1 100 
G 1.56 1.56 1.56 control 1 100 control 1 100 control 1 100 
H 0 0 0 control 1 100 control 1 100 control 1 100 
 
Original data of absorbance value (UDSCC2) 
<>  
1 2 3 4 5 6 7 8 9 10 11 12 
Standard 48 hours 24 hours 12 hours 
A 0.774 0.744 0.770 0.651 0.795 0.576 0.759 0.729 0.508 0.683 0.713 0.687 
B 0.400 0.384 0.383 0.754 0.765 0.578 0.719 0.736 0.489 0.696 0.754 0.673 
C 0.204 0.205 0.228 0.779 0.784 0.578 0.719 0.735 0.563 0.688 0.709 0.651 
D 0.113 0.103 0.097 0.759 0.778 0.526 0.721 0.737 0.546 0.682 0.675 0.645 
E 0.055 0.053 0.045 0.742 0.788 0.000 0.718 0.732 0.093 0.688 0.680 0.226 
F 0.026 0.025 0.015 0.762 0.767 0.003 0.704 0.724 0.096 0.647 0.724 0.249 
G 0.010 0.011 0.010 0.751 0.752 0.001 0.706 0.737 0.078 0.672 0.719 0.224 
H 0.000 0.002 -0.002 0.773 0.744 -0.001 0.646 0.713 0.072 0.623 0.625 0.198 
 
Cells viability after cisplatin treatment (calculate by standard curve) (UDSCC2) 
<>  
1 2 3 4 5 6 7 8 9 10 11 12 
Standard (%) 48 hours (%) 24 hours (%) 12 hours (%) 
A 102.046  97.855  101.551  84.773  105.005  74.450  99.870  95.772  65.103  89.286  93.442  89.845  
B 50.620  48.464  48.384  99.250  100.788  74.752  94.354  96.715  62.606  91.131  99.278  87.919  
C 25.079  25.129  28.062  102.696  103.432  74.656  94.284  96.532  72.679  90.027  92.938  84.870  
D 13.645  12.472  11.693  99.927  102.640  67.566  94.649  96.841  70.392  89.077  88.086  83.953  
E 6.699  6.510  5.585  97.573  103.999  0.465  94.200  96.068  11.256  89.999  88.812  27.896  
F 3.360  3.281  2.069  100.294  101.014  0.841  92.209  95.056  11.669  84.245  94.958  30.758  
G 1.606  1.672  1.541  98.784  98.996  0.568  92.433  96.897  9.495  87.696  94.312  27.551  
H 0.527  0.683  0.262  101.876  97.841  0.353  84.162  93.442  8.776  80.918  81.153  24.266  
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Correct with each control group (UDSCC2) 
48 hours (%) 24 hours (%) 12 hours (%) 
100.00  106.99  75.86  100.00  102.68  69.80  100.00  106.43  102.33  
100.00  102.69  76.16  100.00  103.69  67.12  100.00  113.08  100.14  
100.00  105.39  76.07  100.00  103.50  77.92  100.00  105.86  96.67  
100.00  104.58  68.84  100.00  103.83  75.47  100.00  100.33  95.62  
100.00  105.96  0.47  100.00  103.00  12.07  100.00  101.16  31.77  
100.00  102.92  0.86  100.00  101.91  12.51  100.00  108.16  35.03  
100.00  100.86  0.58  100.00  103.89  10.18  100.00  107.42  31.38  
100.00  99.69  0.36  100.00  100.18  9.41  100.00  92.43  27.64  
 
Viability of UDSCC2 after cisplatin treatment (UDSCC2) 
Treatment time 48 hours 24 hours 12 hours 
Cisplatin  
average std average std average std 
concentration 
0.1 104.91 1.79 103.43 0.51 106.42 5.22 
1 102.36 2.75 102.25 1.59 102.29 7.28 
10 74.23 3.60 80.49 4.98 98.69 3.10 
100 0.57 0.21 11.04 1.49 31.46 3.03 
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Standard Curve: (SCC9) 
Concentration
1 10 100
0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
Graph#1
y = ( (A - D)/(1 + (x/C)^B ) ) + D: A B C D R^2
Std (Standards: Concentration vs MeanValue) 8,94e-4 1,266 32,496 0,884 0,999  
Schematic of 96-wells plate (SCC9) 
<>  
1 2 3 4 5 6 7 8 9 10 11 12 
Standard (%) 48 hours 24 hours 12 hours 
A 100 100 control control 0.1 10 control 0.1 10 control 0.1 10 
B 50 50 control control 0.1 10 control 0.1 10 control 0.1 10 
C 25 25 control control 0.1 10 control 0.1 10 control 0.1 10 
D 12.5 12.5 control control 0.1 10 control 0.1 10 control 0.1 10 
E 6.25 6.25 control control 1 100 control 1 100 control 1 100 
F 3.12 3.12 control control 1 100 control 1 100 control 1 100 
G 1.56 1.56 control control 1 100 control 1 100 control 1 100 
H 0 0 control control 1 100 control 1 100 control 1 100 
Original data of absorbance value (SCC9) 
<>  
1 2 3 4 5 6 7 8 9 10 11 12 
Standard 48 hours 24 hours 12 hours 
A 0.706 0.726 0.762 0.749 0.728 0.748 0.682 0.719 0.724 0.683 0.724 0.769 
B 0.524 0.571 0.727 0.722 0.667 0.700 0.707 0.667 0.699 0.689 0.676 0.703 
C 0.394 0.379 0.695 0.695 0.722 0.714 0.664 0.678 0.692 0.651 0.682 0.730 
D 0.204 0.180 0.692 0.684 0.648 0.714 0.674 0.659 0.635 0.655 0.638 0.658 
E 0.106 0.090 0.701 0.653 0.697 0.103 0.660 0.658 0.439 0.652 0.682 0.695 
F 0.048 0.047 0.682 0.692 0.706 0.107 0.635 0.673 0.479 0.667 0.675 0.635 
G 0.024 0.014 0.691 0.686 0.733 0.101 0.655 0.690 0.381 0.651 0.705 0.550 
H 0.001 -0.001 0.699 0.752 0.645 0.119 0.670 0.693 0.402 0.623 0.553 0.410 
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Cells viability after cisplatin treatment (calculate by standard curve) (SCC9) 
<>  
1 2 3 4 5 6 7 8 9 10 11 12 
Standard (%) 48 hours (%) 24 hours (%) 12 hours (%) 
A 96.636  108.112  137.838  125.535  109.374  125.103  84.897  103.986  107.069  85.200  106.812  145.349  
B 43.645  52.111  108.773  105.413  78.865  93.347  97.123  78.675  92.843  87.776  82.420  94.785  
C 27.350  25.870  90.584  91.018  105.476  100.768  77.514  82.997  89.348  72.967  84.725  110.939  
D 12.515  11.044  89.489  85.897  72.070  100.826  81.728  75.877  67.923  74.330  69.047  75.521  
E 6.683  5.800  94.010  73.609  91.948  6.540  76.272  75.450  32.069  73.440  85.070  90.873  
F 3.348  3.300  84.897  89.208  96.475  6.751  68.103  81.166  37.094  78.942  82.052  67.953  
G 1.850  1.200  88.695  86.560  112.970  6.381  74.434  88.279  26.069  73.068  95.676  48.061  
H 0.052  0.000  92.593  128.276  71.254  7.449  79.944  90.058  28.101  64.604  48.651  28.881  
Correct with each control group (SCC9) 
48 hours (%) 24 hours (%) 12 hours (%) 
100.00 111.29 127.30 100.00 129.98 133.83 100.00 140.01 190.52 
100.00 80.25 94.99 100.00 98.34 116.05 100.00 108.03 124.24 
100.00 107.33 102.54 100.00 103.74 111.68 100.00 111.06 145.42 
100.00 73.33 102.60 100.00 94.84 84.90 100.00 90.50 98.99 
100.00 93.56 6.65 100.00 94.31 40.09 100.00 111.51 119.11 
100.00 98.17 6.87 100.00 101.45 46.37 100.00 107.55 89.07 
100.00 114.95 6.49 100.00 110.35 32.59 100.00 125.41 63.00 
100.00 72.50 7.58 100.00 112.57 35.13 100.00 63.77 37.86 
Viability of SCC9 after cisplatin treatment (SCC9) 
Treatment time 48 hours 24 hours 12 hours 
Cisplatin  
average std average std average std 
concentration 
0.1 93.05 19.05 106.73 15.93 112.40 20.51 
1 94.80 17.47 104.67 8.41 102.06 26.65 
10 106.85 14.09 111.62 20.22 139.79 38.78 
100 6.90 0.48 38.54 6.08 77.26 34.87 
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 7.9 aSMase activity of HNSCC and muscle in mice 
Schematic of 96-wells plate 
 
 
<>  1 2 3 4 5 6 7 8 9 10 11 12 
A T1 T2 M1 M2 T1 T2 M1 M2 
 
Acid buffer 
B T1 T2 M1 M2 T1 T2 M1 M2 
 
Reaction buffer 
C T1 T2 M1 M2 
     
aSMase 0.00002 U 
D T1 T2 M1 M2 
     
aSMase 0.0002 U 
E T1 T2 M1 M2 
     
aSMase 0.001 U 
F T1 T2 M1 M2 
     
aSMase 0.002 U 
G T1 T2 M1 M2 
     
aSMase 0.005 U 
H T1 T2 M1 M2 
     
aSMase 0.02 U 
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Original data of absorbance value 
<> 1 2 3 4 5 6 7 8 9 10 11 12 
A 19558 21458 10716 12752 31079 26735 8974 8560 19 2935 2665 2265 
B 45587 44718 10526 11776 24025 20193 10793 12469 21 2314 2251 2432 
C 30934 24206 13737 10681 29 28 31 34 26 2823 2788 2581 
D 33370 49749 9865 15877 24 38 32 31 19 2707 2638 2751 
E 25628 39701 11553 10089 25 32 38 32 16 4610 4606 4585 
F 33058 31817 22521 17678 29 24 36 46 30 5841 5834 5681 
G 29953 31348 8021 6915 41 27 24 23 34 12624 12177 11752 
H 21683 29886 9521 11620 35 26 39 35 11 25591 45 36 
 
 
Standard curve 
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aSMase release of mice tissue (U) 
No. Tumor-1 Tumor-2 Muscle-1 Muscle-2 
1 0.01596 0.01786 0.00712 0.00916 
2 0.04199 0.04112 0.00693 0.00818 
3 0.02734 0.02061 0.01014 0.00709 
4 0.02978 0.04616 0.00627 0.01228 
5 0.02203 0.03611 0.00796 0.00650 
6 0.02946 0.02822 0.01893 0.01408 
7 0.02636 0.02775 0.00443 0.00332 
8 0.01809 0.02629 0.00593 0.00803 
9 0.02749 0.02314 0.00538 0.00497 
10 0.02043 0.01660 0.00720 0.00888 
Weight of mice tissue (mg) 
No. Tumor-1 Tumor-2 Muscle-1 Muscle-2 
1 0.088  0.060  0.078  0.047  
2 0.131  0.094  0.063  0.062  
3 0.147  0.156  0.085  0.062  
4 0.065  0.113  0.052  0.091  
5 0.048  0.077  0.057  0.042  
6 0.062  0.147  0.111  0.070  
7 0.067  0.064  0.042  0.048  
8 0.037  0.054  0.038  0.060  
9 0.067  0.072  0.050  0.065  
10 0.054  0.069  0.047  0.055  
aSMase release of mice tissue per gram (aSMase U/mg)  
No. Tumor-1 Tumor-2 Muscle-1 Muscle-2 Tumor average Muscle average 
1 0.181 0.298 0.091 0.195 0.240 0.143 
2 0.321 0.437 0.110 0.132 0.379 0.121 
3 0.186 0.132 0.119 0.114 0.159 0.117 
4 0.458 0.408 0.121 0.135 0.433 0.128 
5 0.459 0.469 0.140 0.155 0.464 0.147 
6 0.475 0.192 0.171 0.201 0.334 0.186 
7 0.393 0.434 0.105 0.069 0.414 0.087 
8 0.489 0.487 0.156 0.134 0.488 0.145 
9 0.410 0.321 0.108 0.076 0.366 0.092 
10 0.378 0.241 0.153 0.161 0.309 0.157 
 
Tumor Muscle 
p value 
MEAN SD MEAN SD 
0.359 0.102 0.132 0.030 9.23×10-5 
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